Atacicept for IgAN Patients
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Brief Description
This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to placebo.
Trial Physician / Study Coordinator
US Medical Information ; Merck KGaA Communication Center
Email PhoneSite Name
Research Site
Sponsor
EMD Serono Research & Development Institute, Inc.
Study Drug
Atacicept
Estimated enrollment
30
Estimated end date
June, 2021
Atacicept for IgAN Patients
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Brief Description
This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to placebo.
Trial is for people with
IgA Nephropathy
Study Goal
To determine if Atacicept is well tolerated by IgAN patients and effective at reducing proteinuria.
What is involved for the Patient?
Patients will receive the study drug weekly as a subcutaneous injection for 72 weeks.
About the drug or intervention
Atacicept inhibits the function of specific cells of the immune system.